In last trading session, Heron Therapeutics Inc (NASDAQ:HRTX) saw 1.06 million shares changing hands with its beta currently measuring 1.64. Company’s recent per share price level of $1.69 trading at -$0.03 or -1.74% at ring of the bell on the day assigns it a market valuation of $257.04M. That closing price of HRTX’s stock is at a discount of -132.54% from its 52-week high price of $3.93 and is indicating a premium of 38.46% from its 52-week low price of $1.04.
For Heron Therapeutics Inc (HRTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.03 in the current quarter.
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
Upright in the red during last session for losing -1.74%, in the last five days HRTX remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $1.69 price level, adding 7.69% to its value on the day. Heron Therapeutics Inc’s shares saw a change of 10.46% in year-to-date performance and have moved 1.81% in past 5-day. Heron Therapeutics Inc (NASDAQ:HRTX) showed a performance of 3.68% in past 30-days.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 75.86% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 9. It follows that stock’s current price would drop -195.86% in reaching the projected high whereas dropping to the targeted low would mean a loss of -195.86% for stock’s current value.
Heron Therapeutics Inc (HRTX) estimates and forecasts
This year revenue growth is estimated to rise 10.88% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 37.37M for the same. And 1 analysts are in estimates of company making revenue of 34.25M in the next quarter. Company posted 34.23M and 34.67M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 20.01% during past 5 years.
Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders
RUBRIC CAPITAL MANAGEMENT LP is the top institutional holder at HRTX for having 26.71 million shares of worth $93.5 million. And as of 2024-06-30, it was holding 17.5395 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 8.62 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.6984 of outstanding shares, having a total worth of $30.16 million.
